New delivery method boosts efficiency of CRISPR genome-editing system
The genome-editing technique known as CRISPR allows scientists to clip a specific DNA sequence and replace it with a new one, offering the potential to cure diseases caused by defective genes. For this potential to be realized, however, scientists must find a way to safely deliver the CRISPR machinery and a corrected copy of the DNA into the diseased cells.
MIT researchers have now developed a way to deliver the CRISPR genome repair components more efficiently than previously possible, and they also believe it may be safer for human use. In a study of mice, they found that they could correct the mutated gene that causes a rare liver disorder, in 6 percent of liver cells — enough to cure the mice of the disease, known as tyrosinemia.
“This finding really excites us because it makes us think that this is a gene repair system that could be used to treat a range of diseases — not just tyrosinemia but others as well,” says Daniel Anderson, associate professor in MIT’s Department of Chemical Engineering and a member of MIT’s Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science (IMES).
Anderson is one of the senior authors of a paper describing the findings in the Feb. 1 issue of Nature Biotechnology. Wen Xue, an assistant professor in molecular medicine at the University of Massachusetts Medical School, is also a senior author. The paper’s lead author is Hao Yin, a research scientist at the Koch Institute.
Find and replace
The CRISPR system relies on cellular machinery that bacteria use to defend themselves from viral infection. Researchers have previously harnessed this system to create gene-editing complexes composed of a DNA-cutting enzyme called Cas9 and a short RNA that guides the enzyme to a specific area of the genome, directing Cas9 where to make its cut.
When Cas9 and the short guide RNA targeting a disease gene are delivered into cells, a specific cut is made in the genome, and the cells’ DNA repair processes glue the cut back together, often deleting a small portion of the genome. However, if a corrected copy of the gene is also delivered when the cut is made, the DNA repair can lead to correction of the disease gene, permanently repairing the genome.
In 2014, Anderson and colleagues described the first use of CRISPR to repair a disease gene in an adult animal. In that study, they were able to cure tyrosinemia in mice. However, delivery of the genetic components required a high-pressure injection, a method that can also cause some damage to the liver.
“That was the first demonstration of using CRISPR/Cas9 to do genetic repair in an adult animal,” Anderson says. “We were excited by this demonstration but wanted to find a way to develop a drug form of the repair machinery that would be both safer and more efficient.”
The researchers also wanted to boost the percentage of cells that had the defective gene replaced. In the previous study, about one in 250 liver cells were repaired, which was enough to successfully treat tyrosinemia. However, for many other diseases, a higher percentage of repair would be needed to provide a therapeutic effect.
In the new study, Anderson and colleagues developed a combined nanoparticle and viral delivery system to deliver the CRISPR repair machinery. First, they created a nanoparticle from lipids and messenger RNA (mRNA) that encoded the Cas9 enzyme. The other two components — the RNA guide strand and the DNA for the corrected gene — were embedded into a reprogrammed viral particle based on an adeno-associated virus (AAV).
The researchers first injected the virus about a week before the lipid nanoparticles, giving the liver cells time to begin producing the RNA guide strand and the DNA template. When the nanoparticles carrying the Cas9 mRNA strand were injected, the cells began producing the Cas9 protein, but only for a few days because the mRNA eventually degraded. This is long enough to perform gene repair, but prevents cas9 from lingering in the cells and potentially disrupting other parts of the cells’ genome.
“There’s some concern that if you had Cas9 in your cells for too long of a period of time, it might cause some genomic instability,” Anderson says. “We think the use of the mRNA nanoparticle provides an additional level of safety by making sure the enzyme is not present for too long a period of time.”
With this method, about one in 16 cells had the gene corrected, a 15-fold improvement over the 2014 study. The researchers also found that this approach generated less off-target DNA cutting than methods in which the Cas9 gene is integrated into a cell’s genome.
“We did a genome-scale analysis and we have a very high level of on-target effects but almost no off-target effects,” Yin says.
“This is quite a promising development,” says Terence Flotte, dean of the University of Massachusetts Medical School, who was not part of the research team. “This combination of two different delivery modalities solves a number of hurdles that would otherwise make it difficult to do a gene correction in hepatocytes.”
Read more: Curing disease by repairing faulty genes
The Latest on: CRISPR
via Google News
The Latest on: CRISPR
- Non-Sputum CRISPR-Based Tuberculosis Test Shows High Sensitivity in HIV-Infected Childrenon June 26, 2022 at 11:47 am
The new assay makes a number of modifications to enhance the sensitivity of the CRISPR reaction and allow detection of rare targets.
- Researchers created gene-edited hamsters full of rage in an experiment gone wrongon June 26, 2022 at 7:05 am
While researching how hormones affect animal's social behavior, scientists managed to make gene-edited hamsters full of rage.
- Will CRISPR Stock Double in the Next Year?on June 24, 2022 at 7:23 am
One big Wall Street name thinks it has found a high-quality stock and big winner in this gene-editing companying, with implied upside of more than 100%. Oppenheimer’s Jay Olson was the lead analyst on ...
- Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Aheadon June 23, 2022 at 5:24 pm
Crispr Therapeutics Chief Executive Sam Kulkarni says the next two years of clinical trials and data readouts will give investors, and patients, plenty to cheer about.
- Evercore ISI Group Downgrades CRISPR Therapeutics: Here's What You Need To Knowon June 23, 2022 at 11:08 am
Evercore ISI Group downgraded its rating of CRISPR Therapeutics (NASDAQ:CRSP) to In-Line with a price target of $60.00, changing its price target from $66.00 to $60.00. Shares of CRISPR Therapeutics ...
- Crispr Therapeutics: Innovation Day Showcases Upside Opportunities In Short And Long Termon June 23, 2022 at 9:04 am
CRISPR Therapeutics shares traded as high as $200 18 months ago, but today the share price is $62, and market cap valuation $4.75bn. Read about CRSP here.
- How CRISPR rice could help tackle climate changeon June 22, 2022 at 2:32 pm
Can gene-editing technology CRISPR create new crops that help fight climate change as they grow? That’s what a group of researchers hopes to do with $11 million in funding from ...
- Why CRISPR Therapeutics Stock Is Fallingon June 22, 2022 at 11:26 am
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading lower Wednesday after several analysts adjusted price targets on the stock following the company's Innovation Day.
- Up 24% In A Month, Will CRISPR Stock Continue To See Higher Levels?on June 22, 2022 at 4:00 am
CRISPR Therapeutics stock (NASDAQ: CRSP), a biotechnology gene-editing company focused on developing gene-based medicines for human diseases, has risen a solid 24% in a month, outperforming the ...
- Scientists Used CRISPR to Trace Every Human Gene to Its Functionon June 20, 2022 at 7:00 am
Changing gene expression in over 2.5 million human cells, the technology comprehensively mapped how genetic perturbations alter the cell.
via Bing News